Top Core and Group Health Stories
Cigna researchers see GLP-1s cutting anxiety-related office visits
By Allison BellPeople with diabetes who used semaglutide or other GLP-1 agonists were also less likely to see a provider for depression.
News, insight, and analysis from industry experts to help benefits brokers, consultants and advisors make their way through the tumultuous reformed health care marketplace. Content will help them grow their practices by focusing on a wide range of products, discussing new sales and marketing strategies and highlighting innovative and disruptive brokers who are forging a new path in today's benefits marketplace.
People with diabetes who used semaglutide or other GLP-1 agonists were also less likely to see a provider for depression.